Q3 2025 Tandem Diabetes Care Inc Earnings Call Transcript
Key Points
- Tandem Diabetes Care Inc (TNDM) achieved record third-quarter sales of $249 million, driven by ASP increases and favorable foreign currency dynamics.
- The company reported a significant improvement in gross margin, increasing by 3 percentage points year over year.
- Tandem's strategic initiatives, including modernization of commercial operations and driving innovation, are showing measurable benefits in sales productivity and effectiveness.
- The international expansion is progressing well, with plans to begin direct operations in the UK, Switzerland, and Austria in early 2026.
- The integration of Abbott's Freestyle Libre 3+ with t:slim X2 in the US has received positive user feedback, enhancing the product's appeal.
- New pump starts continue to face pressure, particularly from competitive conversions, impacting overall growth.
- The transition to direct operations in Europe involves a $10 million headwind due to distributor inventory destocking and buybacks.
- Despite improvements, the company still faces challenges in achieving its adjusted EBITDA expectations, with a target of negative 5% of sales for 2025.
- The pharmacy channel expansion, while promising, requires significant internal effort and operational adjustments.
- There is potential for long-term pricing pressure in the pharmacy channel as more competitors enter, which could impact margins.
Good day and thank you for standing by. Welcome to the Tandem Diabetes Care third-quarter 2025 earnings conference call. (Operator Instructions) Please be advised that todayâs conference is being recorded. I would now like to hand the conference over to your speaker today, Susan Morrison, Executive Vice President and Chief Administrative Officer. Please go ahead.
Hello everyone, and welcome to Tandemâs third-quarter 2025 earnings call. Todayâs discussion will include forward-looking statements.
These statements reflect managementâs expectations about future events, our product pipeline, development timelines, and financial performance and operating plans, and speak only as of todayâs date. There are risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in our forward-looking statements, which are described in our press release issued earlier today and under the risk factors portion of our most
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
